Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$28.02 USD
+0.01 (0.04%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $28.03 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MYGN 28.02 +0.01(0.04%)
Will MYGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYGN
INCY or MYGN: Which Is the Better Value Stock Right Now?
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
Other News for MYGN
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
Myriad Genetics announces results from nationwide Cancer Risk Survey
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics Earns 2024 Great Place To Work® Certification™